Systematic Literature Review of Studies Reporting Measures of Functional Outcome or Quality of Life in People with Negative Symptoms of Schizophrenia

References

• Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519–534.
   PubMed Web of Science ®Google Scholar
• Foussias G, Agid O, Fervaha G, Remington G. Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. Eur Neuropsychopharmacol. 2014;24:693–709.
   PubMed Web of Science ®Google Scholar
• Veerman SRT, Schulte PFJ, de Haan L. Treatment for negative symptoms in schizophrenia: a comprehensive review. Drugs. 2017;77:1423–1459.
   PubMed Web of Science ®Google Scholar
• Mosolov SN, Yaltonskaya PA. Primary and secondary negative symptoms in Schizophrenia. Front Psychiatry. 2022;12:766692.
   PubMed Web of Science ®Google Scholar
• Marder SR, Galderisi S. The current conceptualization of negative symptoms in schizophrenia. World Psychiatry. 2017;16:14–24.
   PubMed Web of Science ®Google Scholar
• Gupta M, Holshausen K, Gou L, Bowie C. Measuring negative symptom change in schizophrenia: considering alternatives to self-report. Expert Rev Neurother. 2014;14(8):911–922.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:214–219.
   PubMed Web of Science ®Google Scholar
• Fervaha G, Foussias G, Agid O, Remington G. Impact of primary negative symptoms on functional outcomes in schizophrenia. Eur Psychiatry. 2014;29:449–455.
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441–449.
   PubMed Web of Science ®Google Scholar
• Vita A, Barlati S. Recovery from schizophrenia: is it possible? Curr Opin Psychiatry. 2018;31:246–255.
   PubMed Web of Science ®Google Scholar
• Beck AT, Grant PM, Huh GA, Perivoliotis D, Chang NA. Dysfunctional attitudes and expectancies in deficit syndrome schizophrenia. Schizophr Bull. 2013;39:43–51.
   PubMed Web of Science ®Google Scholar
• Bryl K, Bradt J, Cechnicki A, Fisher K, Sossin KM, Goodill S. The role of dance/movement therapy in the treatment of negative symptoms in schizophrenia: a mixed methods pilot study. J Ment Health. 2020;1:1–11.
   Google Scholar
• Buchanan RW, Panagides J, Zhao J, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol. 2012;32:36–45.
   PubMed Web of Science ®Google Scholar
• Bugarski-Kirola D, Blaettler T, Arango C, et al. Bitopertin in negative symptoms of schizophrenia-results from the Phase III flashlyte and daylyte studies. Biol Psychiatry. 2017;82:8–16.
   PubMed Web of Science ®Google Scholar
• Dunayevich E, Buchanan RW, Chen CY, et al. Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia. Schizophr Res. 2017;182:90–97.
   PubMed Web of Science ®Google Scholar
• Edgar CJ, Blaettler T, Bugarski-Kirola D, Le Scouiller S, Garibaldi GM, Marder SR. Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms. Psychiatry Res. 2014;218:219–224.
   PubMed Web of Science ®Google Scholar
• Rofail D, Regnault A, le Scouiller S, Berardo CG, Umbricht D, Fitzpatrick R. Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertin. Qual Life Res. 2016;25:201–211.
   PubMed Web of Science ®Google Scholar
• Umbricht D, Alberati D, Martin-Facklam M, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry. 2014;71:637–646.
   PubMed Web of Science ®Google Scholar
• Fleischhacker W, Galderisi S, Laszlovszky I, et al. The efficacy of cariprazine in negative symptoms of schizophrenia: post hoc analyses of PANSS individual items and PANSS-derived factors. Eur Psychiatry. 2019;58:1–9.
   PubMed Web of Science ®Google Scholar
• Németh G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389:1103–1113.
   PubMed Web of Science ®Google Scholar
• Hasan A, Wobrock T, Guse B, et al. Structural brain changes are associated with response of negative symptoms to prefrontal repetitive transcranial magnetic stimulation in patients with schizophrenia. Mol Psychiatry. 2017;22:857–864.
   PubMed Web of Science ®Google Scholar
• Wobrock T, Guse B, Cordes J, et al. Left prefrontal high-frequency repetitive transcranial magnetic stimulation for the treatment of schizophrenia with predominant negative symptoms: a sham-controlled, randomized multicenter trial. Biol Psychiatry. 2015;77:979–988.
   PubMed Web of Science ®Google Scholar
• Hill M, Shannahan K, Jasinski S, et al. Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res. 2011;127:41–45.
   PubMed Web of Science ®Google Scholar
• Hirayasu Y, Sato S, Takahashi H, et al. A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia. BMC Psychiatry. 2016;16:66.
   PubMed Web of Science ®Google Scholar
• Kane JM, Yang R, Youakim JM. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study. Schizophr Res. 2012;135:116–122.
   PubMed Web of Science ®Google Scholar
• Kaphzan H, Ben-Shachar D, Klein E. Entacapone augmentation of antipsychotic treatment in schizophrenic patients with negative symptoms; a double-blind placebo-controlled study. Int J Neuropsychopharmacol. 2014;17:337–340.
   PubMed Web of Science ®Google Scholar
• Kayo M, Scemes S, Savoia MG, et al. A randomized controlled trial of social skills training for patients with treatment-resistant schizophrenia with predominantly negative symptoms. Psychiatry Res. 2020;287:112914.
   PubMed Web of Science ®Google Scholar
• Klingberg S, Wölwer W, Engel C, et al. Negative symptoms of schizophrenia as primary target of cognitive behavioral therapy: results of the randomized clinical TONES study. Schizophr Bull. 2011;37(Suppl 2):S98–110.
   PubMed Web of Science ®Google Scholar
• Klingberg S, Herrlich J, Wiedemann G, et al. Adverse effects of cognitive behavioral therapy and cognitive remediation in schizophrenia: results of the treatment of negative symptoms study. J Nerv Ment Dis. 2012;200:569–576.
   PubMed Web of Science ®Google Scholar
• Levkovitz Y, Rabany L, Harel EV, Zangen A. Deep transcranial magnetic stimulation add-on for treatment of negative symptoms and cognitive deficits of schizophrenia: a feasibility study. Int J Neuropsychopharmacol. 2011;14:991–996.
   PubMed Web of Science ®Google Scholar
• Liu CC, Chen CH, Hwu HG, et al. Medium-term course and outcome of schizophrenia depicted by the sixth-month subtype after an acute episode. J Formos Med Assoc. 2012;111:265–274.
   PubMed Web of Science ®Google Scholar
• Mairs H, Lovell K, Campbell M, Keeley P. Development and pilot investigation of behavioral activation for negative symptoms. Behav Modif. 2011;35:486–506.
   PubMed Web of Science ®Google Scholar
• Novick D, Montgomery W, Treuer T, Moneta MV, Haro JM. Real-world effectiveness of antipsychotics for the treatment of negative symptoms in patients with schizophrenia with predominantly negative symptoms. Pharmacopsychiatry. 2017;50:56–63.
   PubMed Web of Science ®Google Scholar
• Palm U, Keeser D, Hasan A, et al. Prefrontal transcranial direct current stimulation for treatment of schizophrenia with predominant negative symptoms: a double-blind, sham-controlled proof-of-concept study. Schizophr Bull. 2016;42:1253–1261.
   PubMed Web of Science ®Google Scholar
• Priebe S, Savill M, Wykes T, et al. Effectiveness of group body psychotherapy for negative symptoms of schizophrenia: multicentre randomised controlled trial. Br J Psychiatry. 2016;209:54–61.
   PubMed Web of Science ®Google Scholar
• Priebe S, Savill M, Wykes T, et al.; NESS team. Clinical effectiveness and cost-effectiveness of body psychotherapy in the treatment of negative symptoms of schizophrenia: a multicentre randomised controlled trial. Health Technol Assess. 2016;20(11):vii–xxiii, 1–100.
   Web of Science ®Google Scholar
• Savill M, Orfanos S, Reininghaus U, Wykes T, Bentall R, Priebe S. The relationship between experiential deficits of negative symptoms and subjective quality of life in schizophrenia. Schizophr Res. 2016;176:387–391.
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Berardo CG, Bugarski-Kirola D, Marder S. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr Res. 2013;150:339–342.
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Badescu S, Palamarchuk P, et al. Personal and social adjustment effects of roluperidone in patients with schizophrenia and negative symptoms: results from an exploratory outcome of a randomized placebo-controlled trial. Schizophr Res. 2019;211:103–104.
   PubMed Web of Science ®Google Scholar
• Röhricht F, Clarke T, Priebe S. Therapeutic processes and clinical outcomes of body psychotherapy in chronic schizophrenia – an open clinical trial. Arts Psychotherapy. 2011;38:196–203.
   Web of Science ®Google Scholar
• Schaefer M, Sarkar S, Theophil I, Leopold K, Heinz A, Gallinat J. Acute and long-term memantine add-on treatment to risperidone improves cognitive dysfunction in patients with acute and chronic schizophrenia. Pharmacopsychiatry. 2020;53:21–29.
   PubMed Web of Science ®Google Scholar
• Schoemaker JH, Jansen WT, Schipper J, Szegedi A. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial. J Clin Psychopharmacol. 2014;34:190–198.
   PubMed Web of Science ®Google Scholar
• Shoja Shafti S, Akbari S. Intractability of deficit syndrome of schizophrenia against adjunctive modafinil. J Clin Psychopharmacol. 2016;36:45–49.
   PubMed Web of Science ®Google Scholar
• Stauffer VL, Millen BA, Andersen S, et al. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr Res. 2013;150:434–441.
   PubMed Web of Science ®Google Scholar
• Sum MY, Tay KH, Sengupta S, Sim K. Neurocognitive functioning and quality of life in patients with and without deficit syndrome of schizophrenia. Psychiatry Res. 2018;263:54–60.
   PubMed Web of Science ®Google Scholar
• Valiengo LDCL, Goerigk S, Gordon PC, et al. Efficacy and safety of transcranial direct current stimulation for treating negative symptoms in schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;77:121–129.
   PubMed Web of Science ®Google Scholar
• Walling D, Marder SR, Kane J, et al. Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in negative and cognitive symptoms of Schizophrenia. Schizophr Bull. 2016;42:335–343.
   PubMed Web of Science ®Google Scholar
• Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101:323–329.
   PubMed Web of Science ®Google Scholar
• Bai YM, Hsiao CY, Chen KC, et al. The development of a self-reported scale for measuring functionality in patients with schizophrenia--self-reported version of the graphic Personal and Social Performance (SRG-PSP) scale. Schizophr Res. 2014;159:546–551.
   PubMed Web of Science ®Google Scholar
• Brissos S, Palhavã F, Marques JG, et al. The Portuguese version of the Personal and Social Performance Scale (PSP): reliability, validity, and relationship with cognitive measures in hospitalized and community schizophrenia patients. Soc Psychiatry Psychiatr Epidemiol. 2012;47:1077–1086.
   PubMed Web of Science ®Google Scholar
• Wu BJ, Lin CH, Tseng HF, et al. Validation of the Taiwanese Mandarin version of the Personal and Social Performance scale in a sample of 655 stable schizophrenic patients. Schizophr Res. 2013;146:34–39.
   PubMed Web of Science ®Google Scholar
• Apiquian R, Elena Ulloa R, Herrera-Estrella M, et al. Validity of the Spanish version of the Personal and Social Performance scale in schizophrenia. Schizophr Res. 2009;112:181–186.
   PubMed Web of Science ®Google Scholar
• Kawata AK, Revicki DA. Psychometric properties of the Personal and Social Performance scale (PSP) among individuals with schizophrenia living in the community. Qual Life Res. 2008;17:1247–1256.
   PubMed Web of Science ®Google Scholar
• Garcia-Portilla MP, Saiz PA, Bousoño M, Bascaran MT, Guzmán-Quilo C, Bobes J. en nombre del grupo de validación de la versión española de la escala de Funcionamiento Personal y Social (PSP). Validation of the Spanish Personal and Social Performance scale (PSP) in outpatients with stable and unstable schizophrenia. Rev Psiquiatr Salud Ment. 2011;4:9–18.
   PubMed Web of Science ®Google Scholar
• Juckel G, Schaub D, Fuchs N, et al. Validation of the Personal and Social Performance (PSP) Scale in a German sample of acutely ill patients with schizophrenia. Schizophr Res. 2008;104:287–293.
   PubMed Web of Science ®Google Scholar
• Nafees B, van Hanswijck de Jonge P, Stull D, et al. Reliability and validity of the Personal and Social Performance scale in patients with schizophrenia. Schizophr Res. 2012;140:71–76.
   PubMed Web of Science ®Google Scholar
• Patrick DL, Burns T, Morosini P, et al. Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Curr Med Res Opin. 2009;25:325–338.
   PubMed Web of Science ®Google Scholar
• Tianmei S, Liang S, Yun’ai S, et al. The Chinese version of the Personal and Social Performance Scale (PSP): validity and reliability. Psychiatry Res. 2011;185:275–279.
   PubMed Web of Science ®Google Scholar
• Gspandl S, Peirson RP, Nahhas RW, Skale TG, Lehrer DS. Comparing Global Assessment of Functioning (GAF) and World Health Organization Disability Assessment Schedule (WHODAS) 2.0 in schizophrenia. Psychiatry Res. 2018;259:251–253.
   PubMed Web of Science ®Google Scholar
• Mausbach BT, Harvey PD, Goldman SR, Jeste DV, Patterson TL. Development of a brief scale of everyday functioning in persons with serious mental illness. Schizophr Bull. 2007;33:1364–1372.
   PubMed Web of Science ®Google Scholar
• Heinrichs RW, Statucka M, Goldberg J, McDermid Vaz S. The University of California Performance Skills Assessment (UPSA) in schizophrenia. Schizophr Res. 2006;88:135–141.
   PubMed Web of Science ®Google Scholar
• Uchino T, Nemoto T, Yamaguchi T, et al. Associations of personality traits with the capacity-performance discrepancy of functional outcome in patients with schizophrenia. Neuropsychiatr Dis Treat. 2019;15:2869–2877.
   PubMed Web of Science ®Google Scholar
• Bromley E, Brekke JS. Assessing function and functional outcome in schizophrenia. Curr Top Behav Neurosci. 2010;4:3–21.
   PubMedGoogle Scholar
• Bilker WB, Brensinger C, Kurtz MM, et al. Development of an abbreviated schizophrenia quality of life scale using a new method. Neuropsychopharmacology. 2003;28:773–777.
   PubMed Web of Science ®Google Scholar
• Priebe S, Huxley P, Knight S, Evans S. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int J Soc Psychiatry. 1999;45:7–12.
   PubMed Web of Science ®Google Scholar
• Heinrichs DW, Hanlon TE, Carpenter WT. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388–398.
   PubMed Web of Science ®Google Scholar
• Wilkinson G, Hesdon B, Wild D, et al. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry. 2000;177:42–46.
   PubMed Web of Science ®Google Scholar
• EUROQOL. EuroQol instruments. Available from: https://euroqol.org/information-and-support/euroqol-instruments/. Accessed May 29, 2024.
   Google Scholar
• Prieto L, Sacristán JA, Hormaechea JA, Casado A, Badia X, Gómez JC. Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin. 2004;20:827–835.
   PubMed Web of Science ®Google Scholar
• König HH, Roick C, Angermeyer MC. Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders. Eur Psychiatry. 2007;22:177–187.
   PubMed Web of Science ®Google Scholar
• Cruz Rivera S, McMullan C, Jones L, Kyte D, Slade A, Calvert M. The impact of patient-reported outcome data from clinical trials: perspectives from international stakeholders. J Patient Rep Outcomes. 2020;4:51.
   PubMedGoogle Scholar
• Marder SR, Daniel DG, Alphs L, Awad AG, Keefe RS. Methodological issues in negative symptom trials. Schizophr Bull. 2011;37:250–254.
   PubMed Web of Science ®Google Scholar
• Topp J, Andrees V, Heesen C, Augustin M, Blome C. Recall of health-related quality of life: how does memory affect the SF-6D in patients with psoriasis or multiple sclerosis? A prospective observational study in Germany. BMJ Open. 2019;9:e032859.
   PubMedGoogle Scholar
• Bellack AS, Green MF, Cook JA, et al. Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop. Schizophr Bull. 2007;33:805–822.
   PubMed Web of Science ®Google Scholar
• Tsakos G, Bernabé E, O’Brien K, Sheiham A, de Oliveira C. Comparison of the self-administered and interviewer-administered modes of the child-OIDP. Health Qual Life Outcomes. 2008;6:40.
   PubMed Web of Science ®Google Scholar
• Wiebe S, Guyatt G, Weaver B, Matijevic S, Sidwell C. Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol. 2003;56:52–60.
   PubMed Web of Science ®Google Scholar
• Burns T, Patrick D. Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatr Scand. 2007;116(6):403–418.
   PubMed Web of Science ®Google Scholar
• Karow A, Wittmann L, Schöttle D, Schäfer I, Lambert M. The assessment of quality of life in clinical practice in patients with schizophrenia. Dialogues Clin Neurosci. 2014;16:185–195.
   PubMed Web of Science ®Google Scholar
• Azaiez C, Millier A, Lançon C, et al. Health related quality of life in patients having schizophrenia negative symptoms - a systematic review. J Mark Access Health Policy. 2018;6(1):1517573.
   PubMedGoogle Scholar
• Granholm E, Holden JL, Mikhael T, et al. What do people with schizophrenia do all day? Ecological momentary assessment of real-world functioning in schizophrenia. Schizophr Bull. 2020;46:242–251.
   PubMed Web of Science ®Google Scholar
• Fulford D, Mote J, Gonzalez R, et al. Smartphone sensing of social interactions in people with and without schizophrenia. J Psychiatr Res. 2021;137:613–662.
   PubMed Web of Science ®Google Scholar
• Lopez-Morinigo JD, Barrigón ML, Porras-Segovia A, et al. Use of ecological momentary assessment through a passive smartphone-based app (eB2) by patients with schizophrenia: acceptability study. J Med Internet Res. 2021;23:e26548.
   PubMed Web of Science ®Google Scholar